Health 57 sources · over 7 days 105 articles

Moderna and Merck's Personalized mRNA Vaccine Cuts Melanoma Recurrence

Moderna and Merck have reported that their personalized mRNA cancer vaccine, tested in a large late-stage trial, significantly reduced melanoma recurrence, marking a major advance in cancer treatment and vaccine technology.

Read the full story → · Latest coverage 26 Aug 2026, 1:00 am UTC

Key moments · 7

Moderna's experimental mRNA cancer treatment progresses

Global News ↗

Moderna and Merck shares soar on mRNA cancer vaccine news

Axios ↗

Moderna, Merck cancer vaccine shows promise in late-stage trial

CNBC International ↗

Landmark trial: mRNA therapy cuts odds of skin cancer return

Scientific American Content: Global Science ↗

Moderna cancer vaccine stops melanoma returning

Nature ↗

This mRNA vaccine could prevent deadliest skin cancer

CBS Top Stories ↗

How a personalised cancer vaccine could cut risk of death by half

Indian Express ↗

Coverage by day

newest first

1 article

2 articles

  1. Biotech Breakout: What's in focus after Moderna's cancer win?
    Breaking News on Seeking Alpha Business & Economy

2 articles

6 articles

  1. SA Asks: What are the most promising oncology companies right now?
    Breaking News on Seeking Alpha Business & Economy

5 articles